Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ProAssurance Corporation (NYSE: PRA), a specialty property and casualty insurance holding company focused on medical professional liability, products liability for medical technology and life sciences, and workers’ compensation insurance. These regulatory documents offer detailed information on ProAssurance’s financial condition, segment performance, governance, and its pending merger with The Doctors Company.
ProAssurance’s periodic reports, such as its Form 10-K and Form 10-Q filings (referenced in the company’s earnings releases and 8-Ks), include consolidated financial statements, segment disclosures for Specialty Property and Casualty, Workers’ Compensation Insurance, Segregated Portfolio Cell Reinsurance, Lloyd’s Syndicate, and Corporate, as well as discussions of key ratios, Non-GAAP measures, and risk factors. Investors use these filings to analyze underwriting results, reserve development, investment income, and capital metrics like book value per share and Non-GAAP adjusted book value per share.
The company’s Form 8-K filings highlight specific material events. In 2025, ProAssurance filed multiple 8-Ks to furnish quarterly earnings releases under Item 2.02, report the June 24, 2025 stockholder vote approving the merger agreement with The Doctors Company under Item 5.07, and describe progress on regulatory milestones such as early termination of the Hart-Scott-Rodino waiting period under Item 8.01. Another 8-K filed in December 2025 under Item 5.02 outlines compensatory arrangements for named executive officers in connection with the merger and explains how these payments relate to Section 280G of the Internal Revenue Code.
On Stock Titan, ProAssurance filings are updated as they are released on EDGAR. AI-powered summaries help explain the contents of lengthy documents, highlight key changes from prior periods, and surface important items such as segment results, merger-related disclosures, and executive compensation arrangements. Users can review Forms 10-K and 10-Q for comprehensive financial information, 8-Ks for transaction and earnings announcements, and other filings that document ProAssurance’s regulatory history and its planned transition to a wholly owned subsidiary of The Doctors Company.
ProAssurance Corporation reported first‑quarter 2026 net income of $8.5 million, reversing a $5.8 million loss a year earlier. Total revenues were $262.6 million, with net premiums earned of $223.5 million and net investment income of $40.0 million. Underwriting benefited from $4.9 million of net favorable prior‑year loss reserve development, while reserve for losses and loss adjustment expenses declined to $3.0 billion. Operating cash flow was negative $21.3 million, largely due to claim payments and changes in other liabilities. Shareholders’ equity slipped to $1.34 billion as unrealized investment losses drove a $17.9 million after‑tax decline in accumulated other comprehensive income.
The company is progressing toward its all‑cash merger with The Doctors Company at $25.00 per PRA share. Multiple insurance regulators, including Alabama, Texas and Vermont, along with Lloyd’s of London and the Cayman Islands Monetary Authority, have granted approvals. Reviews remain pending in California and Pennsylvania, and ProAssurance “continues to anticipate” closing by June 30 2026. The company incurred about $1.4 million of pre‑tax merger‑related costs in the quarter and expects total transaction expenses to be significant.
ProAssurance Corporation reported a solid turnaround in first-quarter 2026 results. Net income was $8.5 million, or $0.16 per diluted share, compared with a loss in the prior-year quarter. Non-GAAP operating income rose to $12.7 million, or $0.25 per diluted share, up 86.7% from 2025.
Total revenues were $262.6 million, down 3.5%, as net premiums earned declined but underwriting and loss expenses fell faster, improving the Non-GAAP combined ratio to 109.9% from 112.2%. Consolidated net investment income increased 8.2%, while book value per share slipped to $25.94 due to lower long-term investment values; Non-GAAP adjusted book value per share edged up to $27.86.
The Specialty P&C segment’s Non-GAAP combined ratio improved to 105.9%, helped by $3.0 million of favorable prior-year reserve development. Workers’ compensation posted a higher 114.1% combined ratio. Management reiterated its plan to close the pending merger with The Doctors Company by June 30, 2026, noting most required insurance regulatory approvals have been obtained and others remain under review.
ProAssurance Corp ownership disclosed: Vanguard Capital Management reports beneficial ownership of 2,619,108 shares of Common Stock, representing 5.09% of the class as reported with a 03/31/2026 time anchor. The filer reports 378,233 shares of sole voting power and 2,619,108 shares of sole dispositive power. The filing is signed 04/30/2026 by Ashley Grim.
ProAssurance Corp ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 2,800,643 shares of Common Stock, representing 5.44% of the class as stated in the filing. The filer reports sole power to vote 19,636 shares and sole dispositive power for 2,800,643 shares.
ProAssurance Corp reports a Schedule 13G/A showing 1,442,782 shares beneficially owned by Dimensional Fund Advisors, equal to 2.8% of common stock. The filing states Dimensional disclaims beneficial ownership and that the shares are owned by affiliated Funds. The filing lists sole voting power of 1,411,907 shares. The signature date is 04/09/2026.
ProAssurance Corporation filed Amendment No. 1 to its annual report to supply updated Part III information on directors, executive pay, ownership, related-party matters and auditor fees. The amendment adds detail on board composition, committee independence, pay philosophy and incentive structures.
The filing describes a pending merger under which ProAssurance will become a wholly owned subsidiary of The Doctors Company, noting most required regulatory approvals have been received and the companies continue to anticipate closing by June 30, 2026. It highlights a pay-for-performance design in which 77% of the CEO’s 2026 target total direct compensation is at risk, 2025 annual incentives for executives ranged from 110% to 161% of target, and 2023–2025 performance shares paid nothing because total shareholder return and book value growth did not meet threshold goals.
ProAssurance Corp Schedule 13G/A: The Vanguard Group amended its ownership filing to report 0 shares of ProAssurance Corp common stock. The amendment explains an internal realignment and disaggregation of certain Vanguard subsidiaries under SEC Release No. 34-39538, with those entities reporting separately.
ProAssurance Corporation executive Noreen Dishart, Executive VP and Chief HR Officer, exercised restricted stock units into common shares and had a portion withheld for taxes. On February 25, 2026, she converted 4,588, 5,987, and 3,101 restricted stock units into the same number of common shares at a stated price of $24.47 per share. To cover tax obligations, 5,917 common shares were disposed of as a tax-withholding transaction, leaving her with 27,740 shares of ProAssurance common stock held directly.
ProAssurance Corporation executive Robert David Francis reported multiple equity award transactions. On February 25, 2026, he exercised Restricted Stock Units that converted into 3,226, 8,765, and 5,890 shares of common stock at a stated price of $24.47 per share. A separate transaction shows 7,711 common shares disposed of to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owned 31,196 common shares, along with multiple tranches of RSUs that vest in annual installments from 2024 through 2029 under the company’s 2014 and 2024 equity incentive plans.
PROASSURANCE CORP Chief Financial Officer Dana S. Hendricks reported multiple equity award transactions involving restricted stock units and common shares on February 25, 2026. Hendricks exercised several batches of restricted stock units, converting 5,890, 7,686, and 3,981 restricted stock units into the same number of common shares, all reported at a transaction price of $24.47 per share for the common stock entries.
In a separate transaction coded F, Hendricks disposed of 7,623 common shares at a reported price of $24.47 per share to satisfy exercise price or tax obligations. Following these transactions, Hendricks directly owned 45,603 shares of common stock and maintained several outstanding restricted stock unit awards with reported balances of 23,720, 7,686, and 11,778 units, which vest in pro rata installments over future years if employment conditions are met.